RudaCure Inc. has today completed the demande de brevet for the eye drop formulation composition of RCI001.
This eye drop composition overcomes the physicochemical limitations of RCI001 by specifying the types and ratios of excipient components, thereby enhancing the stability of the drug.
The patent was filed through Jin International Patent & Law Firm, which has expertise in ophtalmique patents. International patents, notamment PCT applications, are planned to be filed sequentially.